Abstract：Objective:To observe and compare the recent objective response rate and adverse reaction of irinotecan or docetaxe combined with oxaliplatin in the treatment of advanced non-small cell lung cancer(NSCLC). Methods:68 patients with advanced NSCLC were divided into group A consisted of 36 patients received irinotecan plus oxaliplatin and group B consisted of 32 patients received docetaxe plus oxaliplatin with a 21-day regimen. Group A: irinotecan 100 mg/m2,day 1,8; oxaliplatin 130 mg/m2,day 2. Group B:docetaxe 75 mg/m2,day 1;oxaliplatin 130 mg/m2,day 2.Two or more cycles of chemotherapy were completed in each group.Results:68 patients were assessable for efficacy and toxicities.The effective rate in group A was 41.67% and in group B was 31.25％.The effective rate between the two groups had no significant difference(P＞0.05). Group A had higher frequencies of delay diarrhoea and cholinergic syndrome(P＜0.01).The incidence of myelosuppression in group A was significantly lower than the group B (P＜0.05).Conclusions:Irinotecan combined with oxaliplatin is active in the treatment of advanced NSCLC,and the adverse reactions can be tolerated. It is a salvage regimen for advanced NSCLC.
韩啸，张竞竞，王洪亚，韩正全，赵福友. 伊立替康或多西他赛联合奥沙利铂治疗晚期非小细胞肺癌的临床观察[J]. 中华解剖与临床杂志, 2013, 18(4): 295-297.
HAN Xiao,ZHANG Jing-jing,WANG Hong-ya,HAN Zheng-quan,ZHAO Fu-you. Clinical Study of Irinotecan or Docetaxe combined with Oxaliplatin on Patients with Advanced Non-small Cell Lung Cancer. Chinese Journal of Anatomy and Clinics, 2013, 18(4): 295-297.
2013, Vol. 18 
